Bactrazine

Quick links to important sections

Bactrazine

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactrazine

Quick Facts: Bactrazine (Sulfadiazine Silver)

Property Description
Active ingredient Sulfadiazine Silver (INN)
Form Topical Cream
Pharmacological class Topical Antibacterial, Anti-Infective
General use Preventing microbial contamination
Origin Synthetic Salt (Sulfa-derived)

Bactrazine: An Overview of its Identity and Pharmacological Class

Bactrazine is the commercial designation for the pharmaceutical agent Sulfadiazine Silver, which is classified as a Topical Antibacterial and Anti-Infective agent. This medicinal entity functions exclusively at the site of application (Topical Route of Administration) to combat contamination and infection.

Chemically, Sulfadiazine Silver is a synthetic salt derived from the sulfonamide class of drugs, combined with elemental silver. This unique chemical structure is clinically recognized for its effectiveness against a broad range of pathogens and is the reason it falls under the broader Sulfonamide derivative pharmacological group. The active ingredient, Sulfadiazine Silver (INN), is also available under other trade names such as Silvadene.


Composition, Form, and Origin: What is Bactrazine Made of?

The active ingredient in Bactrazine is Sulfadiazine Silver, and it is primarily supplied as a Topical Cream. This product is a single-entity agent, relying solely on the Sulfadiazine Silver molecule for therapeutic effect. The Topical Cream is typically an oil-in-water emulsion that acts as the vehicle, ensuring the active salt is delivered evenly and continuously to the affected area.

Sulfadiazine Silver is included on the Model List of Essential Medicines. This inclusion confirms its essential role in providing localized anti-infective treatment where contamination is a significant concern.


General Purpose: What is the Primary Benefit of Bactrazine?

The primary general purpose of Bactrazine is to establish a strong, protective barrier to prevent and manage microbial contamination, particularly in areas of compromised skin. This benefit stems from its unique dual-action defense mechanism: the silver component immediately works to neutralize germs, while the sulfadiazine component interferes with the internal processes bacteria need to grow and multiply. This synergistic approach provides a broad-spectrum and sustained anti-infective effect, supporting the body's natural healing process by keeping the affected area free from propagating germs.

Regulatory References

  1. Topical
  2. synthetic
  3. sulfonamide class of drugs
  4. Sulfonamide derivative
  5. Model List of Essential Medicines
  6. dual-action defense
  7. silver component
  8. sulfadiazine component
  9. broad-spectrum

What side effects are possible with Bactrazine?

Possible Side Effects and Safety Information

The safety profile for Bactrazine (Sulfadiazine Silver) is structured according to official regulatory documentation, distinguishing between common local reactions and rare, systemic safety concerns.


Documented Adverse Reactions

The most frequently observed adverse reactions, classified as Common in regulatory labeling, are typically limited to the application site. These include a burning sensation, pain, and localized itching.

Adverse effects are categorized by the systems they affect. Skin and Subcutaneous Tissue Disorders cover local reactions. Rare systemic effects, which occur only when there is extensive absorption of the sulfonamide component, may involve the Blood and Lymphatic System Disorders (such as leukopenia) and Renal and Urinary Disorders.


Serious Safety Considerations

Although rare, official labeling documents the possibility of serious systemic reactions historically linked to sulfonamides, particularly with extensive or prolonged use. These include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are severe cutaneous reactions. Leukopenia, a reduction in white blood cell count, is noted to typically manifest two to four days after the initiation of therapy.


Population-Specific Restrictions

Use of Sulfadiazine Silver is contraindicated in infants under two months old and in late-stage pregnancy due to the theoretical risk of kernicterus. Furthermore, the medicine is restricted for individuals with a known history of sulfonamide hypersensitivity and requires caution in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help: Bactrazine

The information below is based on regulatory guidance and describes recognized overdose scenarios and emergency actions.

Documented Overdose Scenarios

Exposure Manifestations Context for Urgency
Ingestion Stomach pain and vomiting when ingested in large amounts. Immediate medical attention is required for severe reactions.
Systemic (Injection) Nausea, vomiting, bone marrow, and kidney failure. Indicates severe, life-threatening overdose risk.
Allergic Reaction Difficulty swallowing or breathing. Requires emergency medical care right away.

Required Emergency Actions

If the product is swallowed, an immediate action is to give the individual water or milk, provided they are not vomiting or have a decreased level of consciousness. For exposure to the eyes or skin, flush the area with copious amounts of water for at least 15 minutes.

When to Seek Immediate Medical Attention

Seek emergency medical care right away if a severe allergic reaction occurs, manifesting as difficulty swallowing or breathing. You must call 911 or emergency services if the person is unconscious, having trouble breathing, or experiencing convulsions. The national toll-free Poison Help hotline can also be contacted for immediate guidance and assistance.

Therapeutic Uses of Bactrazine

Bactrazine (co-trimoxazole) is a combination antibiotic applied across domains where additional symptomatic support is needed for bacterial infections. It is considered relevant in contexts involving heightened systemic burden. This medication is commonly used for managing conditions such as urinary tract infections, Shigellosis (a type of intestinal infection), and Pneumocystis jirovecii Pneumonia (PJP), a serious lung infection.


This therapy is applied in addressing conditions characterized by periods of heightened symptoms. It supports the patient during episodes of heightened discomfort and contributes to easing the overall symptom load in situations involving acute or disruptive symptom patterns.

“This treatment provides supportive relief when symptoms interfere with daily functioning.”

It may assist with maintaining a sense of stability when symptoms are more noticeable, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Applied in scenarios where additional management of discomfort is required

Eligibility and Restrictions for Use

Who Can and Cannot Use Bactrazine (Sulfadiazine Silver)

Bactrazine (Sulfadiazine Silver) eligibility is defined by strict regulatory guidelines focused on population risks, primarily related to the sulfonamide component. Use is contraindicated (must not be used) in several critical groups due to the risk of kernicterus (bilirubin-induced brain damage) or hypersensitivity reactions.

Contraindications and Restrictions

Population Group Eligibility Status Regulatory Basis
Newborns & Infants under 2 months Contraindicated Risk of kernicterus
Pregnant women at term (3rd trimester) Contraindicated Risk of kernicterus in neonate
Known Sulfonamide Allergy Contraindicated Risk of hypersensitivity

Conditional and Restricted Use

Use is restricted or requires caution in patients with certain conditions, reflecting the risk of systemic absorption and accumulation. The medicine should be used with caution in individuals with impaired hepatic (liver) function or impaired renal (kidney) function. Caution is also warranted for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the risk of hemolysis. While generally allowed in children over 2 months of age and adults, use during the first two trimesters of pregnancy is permitted only if the benefit outweighs the risk.

What should I know about interactions with other medicines?

Bactrazine Interactions with other medicines and products

The interaction profile for Sulfadiazine Silver Topical Cream (Bactrazine) is defined by specific chemical incompatibilities at the application site and caution regarding potential systemic absorption risk. This information is derived exclusively from official government regulatory documents.


Category Official Regulatory Classification
Documented Interactions Topical Proteolytic Enzymes; Cimetidine
Interaction Severity Use-With-Caution; Clinically Significant
Regulatory Basis FDA / EMA-aligned prescribing information

Official Interaction Statements:

  • Topical Proteolytic Enzymes: Co-administration with enzymatic debriding agents is documented to result in the chemical inactivation of the enzyme by the silver component. This inactivation leads to a reduction in the debriding agent's therapeutic activity, and joint use is officially not appropriate.
  • Cimetidine: Concomitant use has been formally associated with an increased incidence of leukopenia. This systemic risk is related to the potential for absorbed sulfadiazine to affect hematologic function when combined with Cimetidine.

Population-Specific Caution:

  • In patients with Hepatic or Renal Impairment, official documentation notes a risk of systemic sulfadiazine accumulation. This is due to a decreased rate of drug clearance, which can lead to a heightened potential for sulfonamide-related adverse events.

Connection to the overall interaction profile:

Regulatory documents define the product’s interaction structure primarily through a unique chemical incompatibility at the application site and a pharmacodynamic risk related to the systemic exposure of the sulfonamide component. These factors impose specific constraints on co-administration with other topical agents and systemic medications.

Mechanism of Action

How Bactrazine Works: The Mechanism of Action

Bactrazine (Sulfadiazine Silver) operates via a sustained, dual-action mechanism that combines both structural damage and metabolic interference to reduce microbial proliferation.


Direct Cellular Disruption by the Silver Ion

The core of the mechanism involves the rapid, non-specific action of the silver ion ( Ag^+), which targets multiple vital structures within the microbe. The Ag^+ ion binds chemically to thiol groups on the bacterial cell membrane, causing structural failure and leakage. Once inside the cell, Ag^+ rapidly inactivates key respiratory enzymes required for ATP (energy) synthesis and damages the DNA and RNA. This multi-point molecular assault results in the direct destruction of microbial cells (biocidal action).


Metabolic Pathway Blockade by Sulfadiazine

The second, complementary mechanism involves the Sulfadiazine component, which acts as a structural mimic of PABA. Sulfadiazine competitively inhibits the bacterial enzyme Dihydropteroate Synthetase, a critical step in the microbe's internal synthesis of folic acid. By blocking this essential pathway, the Sulfadiazine component deprives the microbe of the necessary precursors for building new DNA and RNA, halting its ability to grow and multiply (bacteriostatic action).


Sustained Synergy and Mechanistic Constraints

The unique salt structure ensures the continuous, simultaneous release of both components, providing coordinated activity against the microbe’s structure and metabolism. This synergy results in a localized physiological effect that is sustained. However, the mechanism is limited by the local environment, as the active Ag^+ can be bound and deactivated by chloride ions and proteins found in wound exudate, resulting in a reduced concentration of the bioavailable ion.

Dosage and Administration Information

Bactrazine (Silver Sulfadiazine 1% Cream) is a topical medication used exclusively on the surface of the skin, following strict administration principles.

Administration and Dosage Regimen

The medicine is applied as a Topical Cream 1% for external use. The application procedure requires that the affected area be cleansed and debrided prior to the initial application to remove debris. The cream is then applied under sterile conditions, typically using a sterile gloved hand.

The standard regimen requires applying the cream to a thickness of approximately 1/16 inch (or 1 to 3 mm) to ensure the area is covered. Application is performed once to twice daily. It is an official requirement that the affected surface must remain continuously covered with the cream at all times. If the cream is removed by patient activity, such as after hydrotherapy, it must be reapplied immediately.

Duration and Specific Use Rules

The duration of treatment is not fixed but should continue until satisfactory healing has occurred or until the wound site is ready for further intervention, such as grafting. Treatment should not be withdrawn while there remains a possibility of infection, unless an adverse reaction occurs.

Bactrazine use is not recommended in premature infants or in newborn infants during the first 2 months of life.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bactrazine (Sulfadiazine Silver)

The research evidence for Bactrazine, whose active ingredient is Sulfadiazine Silver, primarily focuses on its role as a topical agent studied for use in managing contamination and time to wound closure. Findings describe group patterns and are drawn from studies conducted by scientific and regulatory bodies, providing context but not individual predictions.


Evidence for Use in Managing Burn Wounds

Bactrazine was studied for its use in managing contamination and time to wound closure for patients with partial and full-thickness burn injuries. The evidence base for this application features Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine data from multiple studies. Research has explored outcomes related to infection control and wound healing using study designs that included comparisons to various topical agents and dressings.

Studies monitored specific measurements such as the time required for the wound to fully close (epithelialization) and levels of bacterial colonization. Rates of developing a clinical wound infection were also examined. Findings describe patterns observed in the studies, which often indicated the cream’s pattern of broad anti-infective effects. Some trials described patterns of bacterial load reduction at the application site, a finding that contributes to the broader evidence landscape concerning its topical use.


Research Studies in Other Chronic Skin Wounds

Bactrazine was evaluated in research exploring outcomes for chronic wounds, such as diabetic foot ulcers and pressure sores. This research primarily relies on smaller comparative clinical trials and observational settings. Studies explored the cream’s ability to examine microbial load and contamination in these complex wounds. Findings indicate that research monitored patterns related to microbial load management in these environments. The evidence base for these specific indications is generally considered limited, and the evidence quality varies across studies.


Research Gaps and Areas of Uncertainty

Long-term effects are not fully established. The majority of clinical trials utilized short-term to intermediate follow-up periods, typically concluding once the wound reached complete epithelialization. There is limited information for long-term outcomes such as the final quality of scar tissue. Furthermore, comparative evidence is lacking for some comparisons, meaning the relative advantage in terms of accelerating wound healing compared to all alternatives is not fully established. Research does not determine whether an individual will respond similarly.

Key Studies & References

  1. WHO Model List of Essential Medicines – 23rd List (2023)
  2. Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers: A systematic review

Frequently Asked Questions (FAQ)

Common questions about Bactrazine (FAQ)


Q: Does Bactrazine need to build up in my system to work?

The cream is a topical agent, meaning it works directly at the site of application on the skin. Official information indicates that the drug’s primary antimicrobial effect is localized, targeting bacterial structures. Therefore, its primary activity is understood not to rely on a systemic "build-up" throughout the body, though a small amount may be absorbed.


Q: Is Bactrazine known to cause long-term side effects?

Studies reviewed for regulatory approval primarily utilized short-term to intermediate follow-up periods. The available official research findings indicate that data is limited regarding certain long-term outcomes, such as the final quality of scar tissue.


Q: Can older adults safely use Bactrazine?

Official documents report that clinical studies did not identify overall differences in effectiveness or safety between older adult patients and younger patients. However, as with many medications, greater sensitivity in some older individuals is a possibility that cannot be completely ruled out.


Q: Is there a generic version of Bactrazine?

Bactrazine is a brand name for the drug. The active ingredient is known officially as silver sulfadiazine, which is the generic name for the compound. This generic name is also available under other trade names.


Q: Can Bactrazine be used by people who have a history of allergies?

Official prescribing information lists a strict contraindication for individuals with a known hypersensitivity (severe allergic reaction) to silver sulfadiazine or any medication in the sulfa drug class. Regarding general allergies, it is consistent with good medical practice to inform the healthcare provider of any allergy history.


Q: What does 'contraindicated' mean for Bactrazine?

The term contraindicated means that the medication must not be used in specific situations or patient groups because the risks are deemed to outweigh any potential benefits. For Bactrazine, this applies to newborns under two months old and women who are at term in their pregnancy, based on specific safety and risk concerns noted in regulatory documents.


Q: Why do some people say Bactrazine makes them feel tired?

Official product information indicates that unusual tiredness or weakness is a possible symptom associated with rare, systemic adverse reactions involving the blood, such as leukopenia (a low white blood cell count). This effect is considered associated with the sulfonamide component of the drug.


Q: Can Bactrazine be taken with a common pain reliever like ibuprofen?

Regulatory patient guidance emphasizes the importance of informing the healthcare provider about all prescription and nonprescription medications being taken, including common pain relievers like ibuprofen. This is because systemic absorption of the sulfadiazine component may occur, which could necessitate monitoring or dose adjustments for co-administered drugs.


Q: Can you still drive or operate machinery while taking Bactrazine?

While the cream is a topical treatment, the safety profile notes that rare systemic side effects, such as unusual weakness or dizziness, may occur. These symptoms could potentially affect the ability to drive or operate machinery, and are the types of symptoms that healthcare providers would want to know about.


Q: Does Bactrazine interact with supplements like Vitamin D or iron?

Official regulatory guidance suggests providing the healthcare provider with a complete list of all vitamins, nutritional supplements, and herbal products being taken. This allows the provider to assess the potential for any indirect interactions or the need to monitor for side effects.


Q: Are there official warnings about taking Bactrazine with alcohol?

Regulatory patient guidance suggests that individuals discuss the use of the medicine with alcohol and other substances, like food or tobacco, with a healthcare professional. This is recommended because potential interactions may occur depending on the extent of systemic drug absorption.


Q: Can Bactrazine cause dizziness?

Official product information notes that dizziness is a possible symptom of an infrequent, systemic adverse reaction related to the blood. This symptom is one that healthcare providers typically consider important to monitor, as it may be linked to low blood cell levels.


Q: Why do some sources warn about combining Bactrazine with certain heart medications?

The sulfadiazine component of the cream has the potential to increase the effect of certain other medications, such as some anticoagulants (medicines used to prevent blood clots). Regulatory information notes that co-administration with these drugs is typically managed with careful clinical monitoring.


Q: Does Bactrazine affect fertility?

Regulatory labeling includes a section for information on the impairment of fertility, but specific human data on this topic are limited. Official animal reproductive studies performed showed no evidence that the drug impaired the ability to conceive.


Q: Why is Bactrazine sometimes mentioned with sun sensitivity?

Official sources state that the drug can cause an increased sensitivity of the treated skin to sunlight (a reaction known as photosensitivity). This effect is of particular note when the cream is applied to large body surface areas.


Q: Why do people sometimes need to take a second course of Bactrazine?

Official regulatory requirements state that the treatment should continue until the wound has satisfactorily healed or is ready for a skin graft, and it should not be withdrawn while there is a possibility of infection. The need to start a 'second course' could arise if an infection recurs or persists after a period of treatment cessation.


Q: Are there any specific laboratory tests required before starting Bactrazine?

Regulatory guidance indicates that in patients with extensive burns, it is standard practice for healthcare providers to monitor serum sulfa concentrations and white blood cell counts, given the potential risk of leukopenia (low white blood cell count). Monitoring of renal (kidney) function is also generally part of clinical management.


Q: Can Bactrazine be used by people who are lactose intolerant?

The inactive ingredients detailed in the official regulatory description of the cream typically do not include lactose. However, for individuals with a known intolerance, confirmation of all excipients on the specific product's labeling is usually done by a healthcare professional.


Q: How long does Bactrazine stay in the body after the last dose?

The active component is primarily eliminated from the body by the kidneys. Official pharmacological information indicates that the absorbed sulfonamide component has an elimination half-life of approximately 10 hours.


Q: Why is Bactrazine a prescription-only medicine?

Bactrazine is classified as a prescription-only (Rx) medicine because its use requires professional oversight. Official regulatory bodies classify the product as prescription-only due to factors such as the potential risk of serious systemic side effects and the necessary clinical monitoring, which may include checking blood cell counts.


Q: What happens if I take Bactrazine and then vomit shortly after?

Official guidance emphasizes that the medication is for external use on the skin only. Regulatory text explicitly states that the cream should not be swallowed or allowed to enter the eyes, nose, or mouth.


Q: Does Bactrazine cause changes in mood or anxiety?

Official regulatory safety summaries have noted the possibility of mental or mood changes as a serious adverse reaction linked to the drug's systemic effects. This type of symptom is noted as one that should be discussed promptly with a healthcare provider.


Q: How long does it usually take to notice an effect from Bactrazine?

The local anti-infective effects of the cream are designed to begin shortly after application. However, the overall time required for the treated area to show satisfactory improvement can vary significantly depending on the nature and extent of the wound.

How should Bactrazine be stored and disposed of?

How to Store and Dispose of Bactrazine (Silver Sulfadiazine Cream)

Official labeling defines strict conditions for storing Bactrazine to maintain its effectiveness and safety.


Storage Requirements

Condition Regulatory Rule
Temperature Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep from freezing and protect from light and excessive heat and moisture.
Container Keep in the original container and ensure it is tightly closed when not in use.
Safety The product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired cream must follow local disposal regulations, such as using a drug take-back program. It should not be flushed down the toilet or poured into a drain unless specifically instructed by local authorities. If placed in household trash, unused cream should be mixed with an undesirable substance like coffee grounds and sealed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactrazine found in:

A-Z Index: